Assess the Safety, Reactogenicity, Immunogenicity and Long-Term Persistence of One Intramuscular Dose of GSK Biologicals' MenACWY Conjugate Vaccine vs One Subcutaneous Dose of Mencevax ACWY in Healthy Adults Aged 18-25 Yrs.

Trial Profile

Assess the Safety, Reactogenicity, Immunogenicity and Long-Term Persistence of One Intramuscular Dose of GSK Biologicals' MenACWY Conjugate Vaccine vs One Subcutaneous Dose of Mencevax ACWY in Healthy Adults Aged 18-25 Yrs.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2016

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate; Meningococcal vaccine groups A C Y W-135 polysaccharide
  • Indications Meningococcal infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 29 Sep 2011 Primary endpoint identified as reported by ClinicalTrials.gov.
    • 01 Jan 2009 Results have been reported in Vaccine.
    • 05 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top